BioCentury | Feb 25, 2021
Product Development

Cellarity turning network maps into programs for complex diseases with $123M series B

Flagship-founded single-cell analysis company Cellarity is using its $123 million series B round to advance seven preclinical programs across four complex disease areas, turning the corner from a scientific discovery shop to an integrated drug discovery...
BioCentury | Dec 19, 2020
Management Tracks

RNA pioneer Crooke readies to look beyond Ionis

Another member of biotech’s founding generation is preparing to move on. Ionis Executive Chairman Stanley Crooke, who founded Ionis as Isis in 1989 and over the next three decades was unyielding in his decidation to...
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

While the pandemic has put much of normal life on hold, the biotech industry has continued to hum along, funding and advancing R&D while simultaneously ushering the world into the post-COVID era one...
BioCentury | Nov 25, 2020
Regulation

With Oxlumo’s approval, Alnylam aims to speed access with new value-based pricing framework

With the approval of Oxlumo to treat primary hyperoxaluria, Alnylam is aiming to accelerate patient access to the ultra-rare disease therapy by building on the performance- and prevalence-based pricing...
BioCentury | Nov 19, 2020
Finance

Syncona enters kidney disease space with gene therapy newco Purespring

The launch of Purespring Therapeutics marks the next phase of Syncona’s strategy in moving gene therapy from targeting rare monogenic diseases to more complex, highly prevalent settings. On Thursday, Syncona Ltd. (LSE:SYNC) launched its sixth...
BioCentury | Nov 10, 2020
Product Development

New bar set by BioNTech, Pfizer COVID-19 vaccine could see swift influx of challengers

With interim COVID-19 vaccine efficacy data from BioNTech and Pfizer outstripping the field’s expectations, the results have set a high bar for what could be a rapid wave of readouts accelerated by surges...
BioCentury | Oct 26, 2020
Emerging Company Profile

Serial dealmaker Glick to lead cancer start-up Scorpion with familiar VCs supplying $108M

A VC syndicate that backed IFM and serial dealmaker Gary Glick has launched precision oncology start-up Scorpion, where Glick will be president and CEO, with $108 million in series A funding. Scorpion...
BioCentury | Sep 9, 2020
Product Development

Networking that fueled COVID-19 response should spill into digital sciences and more, says Genmab’s van de Winkel: a BioCentury audio interview

Jan van de Winkel sees a strong future for data sharing and more master protocol trials, fueled by increasing adoption of digital sciences, as companies turn the collaboration they’ve shown in COVID-19 into longer-term productive...
BioCentury | Aug 28, 2020
Deals

BARDA enlisting start-ups in fight against COVID-19 via JLABS collaboration

A collaboration between JLABS and BARDA gives the government agency access to start-ups that it needs to fast track new, innovative COVID-19 therapies and diagnostics it otherwise would struggle...
BioCentury | Jun 2, 2020
Finance

Hillhouse-backed $160M series B round to drive Genor’s first candidate to the market

Genor plans to establish a commercial team and take its first checkpoint inhibitor to market for a new indication after raising a $160 million series B round led by existing investor Hillhouse Capital. New investors...
Items per page:
1 - 10 of 244
BioCentury | Feb 25, 2021
Product Development

Cellarity turning network maps into programs for complex diseases with $123M series B

Flagship-founded single-cell analysis company Cellarity is using its $123 million series B round to advance seven preclinical programs across four complex disease areas, turning the corner from a scientific discovery shop to an integrated drug discovery...
BioCentury | Dec 19, 2020
Management Tracks

RNA pioneer Crooke readies to look beyond Ionis

Another member of biotech’s founding generation is preparing to move on. Ionis Executive Chairman Stanley Crooke, who founded Ionis as Isis in 1989 and over the next three decades was unyielding in his decidation to...
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

While the pandemic has put much of normal life on hold, the biotech industry has continued to hum along, funding and advancing R&D while simultaneously ushering the world into the post-COVID era one...
BioCentury | Nov 25, 2020
Regulation

With Oxlumo’s approval, Alnylam aims to speed access with new value-based pricing framework

With the approval of Oxlumo to treat primary hyperoxaluria, Alnylam is aiming to accelerate patient access to the ultra-rare disease therapy by building on the performance- and prevalence-based pricing...
BioCentury | Nov 19, 2020
Finance

Syncona enters kidney disease space with gene therapy newco Purespring

The launch of Purespring Therapeutics marks the next phase of Syncona’s strategy in moving gene therapy from targeting rare monogenic diseases to more complex, highly prevalent settings. On Thursday, Syncona Ltd. (LSE:SYNC) launched its sixth...
BioCentury | Nov 10, 2020
Product Development

New bar set by BioNTech, Pfizer COVID-19 vaccine could see swift influx of challengers

With interim COVID-19 vaccine efficacy data from BioNTech and Pfizer outstripping the field’s expectations, the results have set a high bar for what could be a rapid wave of readouts accelerated by surges...
BioCentury | Oct 26, 2020
Emerging Company Profile

Serial dealmaker Glick to lead cancer start-up Scorpion with familiar VCs supplying $108M

A VC syndicate that backed IFM and serial dealmaker Gary Glick has launched precision oncology start-up Scorpion, where Glick will be president and CEO, with $108 million in series A funding. Scorpion...
BioCentury | Sep 9, 2020
Product Development

Networking that fueled COVID-19 response should spill into digital sciences and more, says Genmab’s van de Winkel: a BioCentury audio interview

Jan van de Winkel sees a strong future for data sharing and more master protocol trials, fueled by increasing adoption of digital sciences, as companies turn the collaboration they’ve shown in COVID-19 into longer-term productive...
BioCentury | Aug 28, 2020
Deals

BARDA enlisting start-ups in fight against COVID-19 via JLABS collaboration

A collaboration between JLABS and BARDA gives the government agency access to start-ups that it needs to fast track new, innovative COVID-19 therapies and diagnostics it otherwise would struggle...
BioCentury | Jun 2, 2020
Finance

Hillhouse-backed $160M series B round to drive Genor’s first candidate to the market

Genor plans to establish a commercial team and take its first checkpoint inhibitor to market for a new indication after raising a $160 million series B round led by existing investor Hillhouse Capital. New investors...
Items per page:
1 - 10 of 244